Recent Updates — HURA
On October 9, 2026, TuHURA Biosciences drew an additional $650,000 from its existing revolving credit facility with Parkview Holdings One LLC. The loan agreement, originally entered into on April 21, 2026, provides for a maximum availability of $50 million and matures on April 21, 2031. The company intends to use the proceeds for general corporate purposes. TuHURA Biosciences operates in the biotechnology industry, focusing on drug discovery and development.
TuHURA Biosciences, Inc. borrowed an additional $650,000 under its existing revolving credit facility with Parkview Holdings One LLC on September 21, 2026. The loan agreement, originally entered into in April 2026, provides a maximum availability of $50 million and matures on April 21, 2031. The company intends to use the proceeds for general corporate purposes. TuHURA Biosciences operates as a clinical-stage biotechnology company focused on developing therapies for rare diseases.
TuHURA Biosciences, Inc. borrowed an additional $650,000 under its existing revolving credit facility with Parkview Holdings One LLC on September 14, 2026. The funds are intended for general corporate purposes. This draw is part of a broader Loan Agreement established in April 2026 that provides up to $50 million in availability and matures in April 2031. TuHURA Biosciences operates as a clinical-stage biotechnology company focused on developing therapies for rare diseases.
TuHURA Biosciences adopted the 2026 Inducement Equity Incentive Plan on September 10, 2026, reserving 5,000,000 shares of common stock for issuance to new employees as a material inducement. The plan allows grants of nonqualified stock options and other equity awards but excludes incentive stock options, with exercise prices set at or above the closing market price on the grant date. No awards have been granted yet, and the company will announce future grants via press release in compliance with Nasdaq Listing Rule 5635(c)(4). This biotechnology company develops therapies for rare diseases.
TuHURA Biosciences, Inc. borrowed $650,000 on August 20, 2026, under a revolving credit facility established with Parkview Holdings One LLC in April 2026. The loan agreement provides for a maximum availability of $50 million and matures on April 21, 2031. The company intends to use the proceeds for general corporate purposes. TuHURA Biosciences operates as a clinical-stage biotechnology company focused on developing therapies for rare diseases.
TuHURA Biosciences held its 2026 Annual Meeting on August 18, 2026. Stockholders approved the issuance of 1,878,287 shares of common stock to Parkview Holdings One LLC as a loan fee under a $50 million revolving credit facility entered into in April 2026. The company also elected six directors: James Bianco, James Manuso, Alan List, George Ng, Robert E. Hoffman, and Craig Tendler. Shareholders ratified the advisory vote on executive compensation, selected a three-year frequency for future say-on-pay votes, and reappointed Cherry Bekaert LLP as independent auditor. These are routine governance actions without material financial impact. TuHURA Biosciences operates in the biotechnology industry, focusing on drug discovery.